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Abstract: Several randomized controlled trials (RCTs) and meta-analyses support the benefits of 
flavanols on cardiometabolic health, but the factors affecting variability in the responses to these 
compounds have not been properly assessed. The objectives of this meta-analysis were to 
systematically collect the RCTs-based-evidence of the effects of flavanol-containing tea, cocoa and 
apple products on selected biomarkers of cardiometabolic risk and to explore the influence of 
various factors on the variability in the responses to the consumption of these products. A total of 
120 RCTs were selected. Despite a high heterogeneity, the intake of the flavanol-containing 
products was associated using a random model with changes (reported as standardized difference 
in means (SDM)) in body mass index (−0.15, p < 0.001), waist circumference (−0.29, p < 0.001), 
total-cholesterol (−0.21, p < 0.001), LDL-cholesterol (−0.23, p < 0.001), and triacylglycerides (−0.11, p = 
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0.027), and with an increase of HDL-cholesterol (0.15, p = 0.005). Through subgroup analyses, we 
showed the influence of baseline-BMI, sex, source/form of administration, medication and country 
of investigation on some of the outcome measures and suggest that flavanols may be more effective 
in specific subgroups such as those with a BMI ≥ 25.0 kg/m2, non-medicated individuals or by 
specifically using tea products. This meta-analysis provides the first robust evidence of the effects 
induced by the consumption of flavanol-containing tea, cocoa and apple products on weight and 
lipid biomarkers and shows the influence of various factors that can affect their bioefficacy in 
humans. Of note, some of these effects are quantitatively comparable to those produced by drugs, 
life-style changes or other natural products. Further, RCTs in well-characterized populations are 
required to fully comprehend the factors affecting inter-individual responses to flavanol and 
thereby improve flavanols efficacy in the prevention of cardiometabolic disorders. 
Keywords: flavanols; tea; cocoa; apple; cardiometabolic disorders; meta-analysis; interindividual 
variability; blood lipids; body mass index; waist circumference 
 
1. Introduction 
Metabolic disorders, principally, abdominal obesity, dyslipidemia (high levels of 
triacylglycerides (TAGs) and low levels of high-density lipoprotein (HDL)), and insulin resistance 
have been associated to an increased risk of Type-2 diabetes mellitus (DM) and cardiovascular 
diseases (CVDs). CVDs remain the number one cause of death in developed countries and their 
prevalence is increasing rapidly in developing nations and in adolescents [1]. It is now well 
established from population studies that some aspects of CVDs risk can be modulated by various 
dietary interventions including an increased consumption of plant foods [2], as part of a healthy 
balanced diet. In addition to other protective compounds (i.e., fiber and vitamins), plant foods are an 
exclusive and abundant source of phytochemicals, a large and diverse group of compounds which 
exhibit an array of biological activities. The intake of these bioactive compounds are thought to 
contribute to the health benefits associated with the consumption of such foods [3]. Polyphenols are 
some of the most abundant phytochemicals in plant foods and increasing evidence from cohort 
studies indicate that the intake of some of these compounds such as diverse flavonoids and/or, 
importantly, some of their derived microbial metabolites (e.g., enterolactone) may help to reduce the 
development of CVDs and CVDs mortality risk [4–7]. This evidence is supported by animal and 
clinical studies reporting beneficial effects of the consumption of some polyphenol-rich foods or 
pure compounds on CVDs risk factors such as blood cholesterol, blood pressure, endothelial 
function and arterial stiffness [8]. 
Polyphenols encompass several families of compounds, the most represented in plant foods 
being phenolic acids and flavonoids [9]. A major group of flavonoids is constituted by flavanols that 
are abundant in green tea, red wine, cocoa and various fruits such as apples [10]. A summary of the 
major flavonoids present in tea (green and black), cocoa powder and apple is shown in Table S1. The 
assessment of daily intakes of flavanols across Europe revealed a large variation between countries 
(from 200 to 800 mg/day) depending on their dietary habits and the intake of tea [11]. The flavanol 
group is composed primarily of the epicatechin and catechin monomers, and of their oligomeric and 
polymeric forms, the procyanidins. Flavanol monomers and dimeric procyanidins are bioavailable. 
They undergo extensive phase II conjugation and are found in the blood circulation mostly as 
O-methylated, sulfated and glucuronidated conjugates (nM to μM range) [12,13]. In contrast, the 
procyanidins polymers are not absorbed and do not contribute to the systemic pool of flavanols in 
humans [14]. 
Human studies remain essential to understanding the effects of the plant bioactive compounds 
on health and thus, an increasing number of randomized controlled trials (RCTs) with 
flavanol-containing products have been carried out over the past two decades. Meta-analyses 
constitute a useful tool to integrate the accumulated RCTs and review the evidence in humans. Some 
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of the main problems affecting the results of meta-analyses are the usually limited number of studies 
included as well as a range of factors that introduce heterogeneity in the findings. Identifying the 
factors underlying variability, as well as developing new and innovative methodologies to account 
for such variability constitute an overarching goal to ultimately optimize the beneficial health effects 
of plant food bioactives. Among the potential factors involved in such heterogeneity are: (i) factors 
inherent to the individuals: (epi) genetic factors, gut microbiota, baseline conditions (BMI, 
medication), sex, health status, ethnicity, and age; and (ii) factors intrinsic to the type of study 
(design, duration, dose, and type of product) [15]. 
The main goals of the present study were: (i) to systematically review and appraise, through 
meta-analysis, the impact of flavanol-containing tea, cocoa and apple products, three main sources 
of flavanols, on selected biomarkers of cardiometabolic risk, i.e., BMI, WC and blood lipid levels 
(total-, LDL-, HDL-cholesterol and TAGs); and (ii) to further explore some of the factors that may be 
implicated in the inter-individual variability in the response to the consumption of these 
flavanol-containing products. 
2. Materials and Methods  
This systematic review and meta-analysis followed the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) statement guidelines [16], the Cochrane Handbook for 
Systematic Reviews of Interventions [17], and the Centre for Reviews and Dissemination’s guidance 
for undertaking reviews in health care [18]. The protocol for this review was registered in the 
International Prospective Register of Systematic Reviews (PROSPERO, www.crd.york.ac.uk/ 
prospero/index.asp) with the registration number CRD42016033878. 
2.1. Search Strategy 
A comprehensive search on PubMed and Web of Science databases was conducted in July 2015. 
Search terms included a combination of keywords referring to: (1) bioactive (polyphenols, 
flavonoids, flavanols, flavan-3-ol, (epi)catechin, (epi)gallocatechin gallate, theaflavins, thearubigin, 
and procyanidin); (2) food source (apple, tea, and cocoa); (3) type of study and participants (trial, 
experiment, study, intervention; human, subjects, men, women, patients, volunteers, and 
participants); and (4) cardiometabolic outcomes (BMI, WC, total cholesterol, LDL cholesterol, HDL 
cholesterol, and TAGs). No type of restriction was applied during the electronic searches.  
2.2. Study Selection and Data Extraction 
Two authors independently assessed all papers and in the case of disagreement, discussed 
findings to reach a consensus, or in the absence of resolution, a third author was contacted. Studies 
included in the meta-analysis were limited to human RCTs testing the effect of flavanol-containing 
tea, cocoa or apple products, which had a control group receiving a placebo and measured one or 
more of the defined outcomes (BMI, WC, total cholesterol, LDL cholesterol, HDL cholesterol, or 
TAGs). Manuscripts written in any European language were included, whereas other manuscripts 
were excluded. Additionally, the studies with the following characteristics were excluded: studies 
with flavanol-rich food sources other than tea, cocoa or apples; and studies with multifactorial 
interventions (i.e., flavanols given as a part of a multicomponent treatment; dietary or physical 
activity co-intervention). Data extraction was performed in duplicate by two authors, 
independently, and cross-checked by a third author using a standardized data extraction form. 
Extracted data included publication details (year of publication, contact details, clinical trial and 
registration number); participant characteristics (geographical origin, total number of participants 
included in the study and in the analysis, sex distribution, age, ethnicity, health status, menopausal 
status, smoking habits, and use of medication); study setting and design (cross-over or parallel 
design, duration of the intervention, number of arms and description, number of participants 
located in each arm and completing the study, composition of test and placebo, and dose and mode 
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of administration); and outcomes (type of sample, changes in the outcome, values before and after 
intervention, and p-value). 
2.3. Assessment of Quality and Data Analysis 
The quality of the studies was assessed based on the Cochrane Collaboration measurement 
with some modifications [19]. The specific items used for the assessments are detailed in a previous 
meta-analysis following the same protocol [7]. 
Data for each outcome were analyzed using the Comprehensive Meta-Analysis Software, 
version 3.0 (Biostat, Englewood, NJ, USA) [20]. The free scale index standardized difference in 
means (SDM) was used to combine data from the highest number of collected valid studies, 
increasing the pool of studies and the power to detect significant differences. SDM, standard error 
(SE) and the corresponding 95% confidence intervals (CI) were calculated and pooled using random 
effects models to determine test/placebo differences across studies. Statistical heterogeneity between 
studies was assessed by using the Cochran Q test, the between-studies variance (T2) and I2 (an 
estimate of the proportion of variance across studies caused by heterogeneity rather than by random 
errors) where I2 values equal to 25%, 50% and 75% were considered as low, moderate and high 
heterogeneity, respectively. Publication bias was assessed visually with funnel plots and statistically 
by applying the Egger’s regression test. Further assessment of the possible associations between the 
overall changes attributed to the supplementation with the flavanols and the duration of the 
intervention was examined using random-effects meta-regression analysis. Using the random 
model, we have additionally estimated the overall effect size as the difference in means (DM) and 
95% CI. 
Subgroup analyses were conducted to explore potential factors that may introduce 
heterogeneity into the studies and influence the inter-individual variability in the response to 
supplementation with the flavanol-containing products. We selected those factors that were more 
clearly described throughout articles (Table 1). We included factors that might be attributed to some 
of the individuals’ characteristics, such as baseline BMI, sex, smoking habits and medication/health 
status. Age or ethnicity could not be assessed due to unclear reporting. We also included 
stratification by the country in which the study was carried out, the source and form of 
administration of the flavanols, as well as the type of diet reported to be followed during the 
intervention. For each subgroup, the pooled effects (SDM) and the significance of this value were 
estimated. Additionally, statistical comparisons between subgroups were performed by applying a 
random-effects analysis and calculation of the between-categories Q statistic, the p-value and the R2 
index (proportion of between-studies variance explained by each factor or covariate). Using some of 
the factors that partially explained some of the between-studies variance for a particular variable, we 
applied a multiple meta-regression analysis with a random-effects model to search for a potential 
combination of factors that best explained the between-study variance for this variable. Statistical 
significance of the findings was as follows: p-value < 0.05 was considered significant, while p-value ≥ 
0.05 and < 0.1 was considered marginally significant. 
Table 1. Potential factors influencing the heterogeneity in the responses to the supplementation with 
flavanols-containing products investigated in this meta-analysis. 
Factors  
Baseline BMI <25.0 a (normal and/or underweight) ≥25.0 (overweight and/or obese) 
Sex Women Men 
Smoking Non-smokers Smokers 
Country 
where the 
study was 
undertaken 
East Asian 
countries 
(Japan, Korea, 
China, 
Thailand, 
Taiwan) 
All other 
countries 
North 
America 
(USA, 
Canada) 
European countries 
Non-Mediterranean countries 
(Denmark, Finland, The 
Netherlands, Germany, Poland, 
UK, Switzerland) 
Mediterranean 
countries (Italy, Spain, 
Portugal, Greece) 
Medication Yes No 
Healthy vs. Healthy Individuals Individuals Different disorders: overweight and/or obese, 
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non-healthy individuals b at a risk of 
disease c  
with a 
reported 
disease d 
dyslipidemia, glucose disorders, blood pressure disorders, 
mixed e 
Source of 
flavanols 
Cocoa 
products 
Apple 
products 
Tea 
products 
Tea drinks 
Tea 
extracts 
(capsules, 
powder) 
Tea purified 
EGCG  
Diet during 
intervention 
Controlled diet 
Usual diet  
(includes usual with some restrictions and NR) 
a: BMI cut-off values as established by the WHO; b: Includes individuals specifically reported as 
healthy and not medicated (in some cases medication was not reported, NR); c: Includes individuals 
not medicated that were overweight and/or obese, or specifically indicated to be borderline, mild 
condition or at risk of a disease; d: Includes individuals with one or more than one of the following 
disorders: dyslipidemia, glucose disorders or type-2 diabetes, blood pressure disorders 
(hypertension), medicated obesity, metabolic syndrome (most cases were also medicated but in some 
cases medication was NR); e: Individuals reported to have only one of the specified disorders. 
3. Results 
3.1. Description of the Included Studies 
A total of 1409 articles were initially identified through the search on the electronic databases. 
After removal of duplicates and screening, 188 trials were selected for data extraction. After detailed 
analysis of the full text, 71 articles were excluded, due to lack of relevant outcomes, aspects of study 
design or publication language. The final number of articles selected for meta-analysis was selected 
from a total of 117 articles published between 1997 and July 2015 (included) [21–137]. The detailed 
study selection flow diagram is shown in Figure 1. 
 
Figure 1. Flow diagram showing the study selection process. 
3.2. Quality and Characteristics of the Selected Studies 
Most of the studies (70%) were classified as studies with a moderate to low risk of bias (quality 
score ≥5.0 and <8.0 or ≥8.0 and ≤10.0, respectively) while 30% of the studies obtained a low quality 
score (<5.0) and were considered as a high risk of bias. 
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The studies were carried out in countries distributed over five continents: Asia (Japan, Korea, 
China, Taiwan, Thailand, Saudi Arabia, and Iran), North America (USA and Canada) and Latin 
America (Brazil and Mexico), Europe (Denmark, Finland, The Netherlands, Germany, Poland, UK, 
Switzerland, Italy, Spain, Portugal, and Greece), Africa (Mauritania, South Africa, and Republic of 
Mauritius), and Australia. Thus, they were considered representative of a global population. The 
participants in these studies also represent a mixed population of men and women ranging from 
young adults to elderly participants, and with a higher prevalence of individuals with a BMI ≥ 25.0 
kg/m2 (overweight and/or obese volunteers). The quality and depth of reporting of the factors 
potentially contributing toward inter-individual variability of the effect of flavanols varied among 
studies. The smoking habits were not reported in most studies but for those studies that did, the 
participants were typically non-smokers or a mixed sample population. Only two studies [34,57] 
were carried out specifically with smokers. The total sample population included healthy 
individuals, overweight and/or obese individuals as well as individuals with an incipient or with a 
reported chronic risk factor or metabolic disease, comprising principally hypertension, 
hyperlipidemias, type-2 diabetes, metabolic syndrome, atherosclerosis, coronary artery disease and 
heart failure. Among these, some participants were taking medication, others were not medicated or 
medication use was not reported. Studies were selected if the source of flavanols was tea, cocoa, or 
apple provided as liquid (tea drinks, cocoa beverages, and apple juice) or solid (powder or extracts 
in capsules, snacks, tablets, and foods) forms. Interventions ranged typically 1–6 months, during 
which participants followed either a controlled diet or their habitual diets. 
3.3. Overall Impact of the Supplementation with Flavanol-Containing Tea, Cocoa or Apple Products on Blood 
Lipids, BMI and WC 
The number of RCTs varied in function of the outcome measure studied, from 46 to 120 trials, 
recruiting a total high number of participants ranging from 2875 to 5931 individuals. Forest plots 
detailing weighted SDM, SE, 95% confidence intervals and relative weight for the impact of 
supplementation with flavanol-containing tea, cocoa or apple products on BMI, WC, and blood lipid 
levels are shown in Figures S1–S6. Visual inspection of the Funnel plots (Figures S7–S12) evidenced 
symmetrical shapes and absence of publication bias in the case of WC, total cholesterol, LDL, HDL 
and TAGs. Some asymmetry was however detected for BMI. These results were further confirmed 
by Egger’s regression. A summary of the random overall effects for each lipid and obesity-related 
variable, heterogeneity and bias analyses is presented in Table 2. 
Table 2. Overall changes (SDM), heterogeneity and publication bias analyses for the impact of 
flavanol-containing products on BMI, WC and blood lipids levels. 
 n NT NS NC SDM 95% CI Z p-Value Tau2 Q df (p-Value) I2 (%) 
Egger’s Regression
Intercept p-Value 
(2-Tailed)
BMI 74 4156 2127 2029 −0.153 −0.227, −0.078 −4.009 <0.001 0.027 99.6 73 (0.021) 26.7 1.04 0.024 
WC 46 2875 1478 1397 −0.293 −0.438, −0.147 −3.932 <0.001 0.168 156.7 45 (<0.001) 71.3 −1.47 0.101 
TC 112 5812 2982 2830 −0.214 −0.328, −0.099 −3.651 <0.001 0.273 479.1 111 (<0.001) 76.8 −0.76 0.226 
LDL-C 105 5726 2928 2798 −0.235 −0.345, −0.125 −4.171 <0.001 0.229 408.0 104 (<0.001) 74.5 −0.46 0.459 
HDL-C 112 5928 3023 2905 0.152 0.047, 0.256 2.836 0.005 0.214 408.0 111 (<0.001) 72.8 0.72 0.208 
TAGs 120 5931 3023 2908 −0.114 −0.215, −0.013 −2.213 0.027 0.209 407.7 119 (<0.001) 70.8 −0.33 0.570 
BMI: Body Mass Index; WC: Waist Circumference; TC: Total Cholesterol; LDL-C: Low density 
Lipoprotein Cholesterol; HDL-C: High Density Lipoprotein Cholesterol; TAGs: Triglycerides; n: total 
number of studies included in the analysis; NT: number of total participants; NS: number of 
participants in the supplemented group; NC: number of participants in the control group; SDM: 
standardized difference in means; 95% CI: lower and upper confidence limits for the average SDM: 
df: degrees of freedom; Z: statistic for testing the significance of the average SDM; Tau2: 
between-studies variance; Q: heterogeneity statistic; I2: heterogeneity index. 
Despite a high heterogeneity across the studies (I2 = 70–77% for most variables except for BMI 
which was more moderate, I2 = 26.7%), the overall pooled analysis (shown as SDM) significantly 
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confirmed a reduction of BMI (−0.153, p-value < 0.001), WC (−0.293, p-value < 0.001), blood total 
cholesterol (−0.214, p-value < 0.001), LDL (−0.235, p-value < 0.001), and TAGs (−0.114, p-value = 0.027). 
HDL levels were also significantly increased (0.152, p-value = 0.005). Sensitivity analyses were 
carried out using the leave-one-out approach where the meta-analysis was performed with each 
study removed in turn. The pooled estimates consistently showed a similar effect and significance 
emphasizing the robustness of these results and that the effect was not driven by any particular 
study (data not shown). Further support of these results was found by a significant relationship 
between the duration of the supplementation with the flavanol products and the reduction of WC; 
total-, LDL- and HDL-cholesterol; and TAGs using random-effects meta-regression analysis. 
Regression coefficients and p-values for each variable can be seen in Table S2. 
3.4. Analysis of the Potential Factors Influencing Inter-Individual Responses to Flavanols Consumption 
3.4.1. Stratification by the Individuals’ Baseline BMI, Sex, Smoking, and Country 
Following stratification by the baseline BMI (Table 3), the effects of the flavanol-containing 
products on BMI, WC, total- and LDL-cholesterol remained significant only in those studies carried 
out in overweight/obese volunteers (BMI ≥ 25.0 kg/m2). HDL-cholesterol levels were also increased 
in this subgroup (p = 0.063) whereas the reducing effects on TAGs levels were not significant in any 
of the two subgroups. Statistical comparison between ≥25.0 vs. <25.0 kg/m2 subgroups did not reach 
significance for any of the variables investigated. Of note, 61% of the total between-study variance in 
BMI could be explained by the respective baseline BMI values (total between Q = 2.53, p-value = 
0.112, R2 index = 0.61). 
Regarding stratification by sex, the reduction of WC was significant in both men and women 
after intervention with flavanol-containing products. However, total- and LDL-cholesterol were 
significantly reduced only in female whereas BMI was significantly lowered only in male. The effects 
on HDL and TAG levels were no longer significant after stratification by sex (Table 3). Between 
groups comparison indicated a difference between sexes (total between Q = 2.833, p-value = 0.092) 
and a considerable contribution of the sex to the between-study variance for BMI (R2 index = 1.0).  
The reduction of BMI, WC, and total- and LDL-cholesterol in response to the 
flavanol-containing products was significant in studies carried out in non-smoker volunteers. It was 
not possible, however, to establish a comparison with habitual smokers due to the very low number 
of studies carried out with this type of volunteers (n = 2 studies).  
Comparison between studies carried out in East Asian countries (assuming Asian ethnicity) 
against those carried out elsewhere evidenced similar results for BMI, WC, total and LDL cholesterol 
in both subgroups although the results were slightly less significant in the East Asian subgroup. A 
small proportion (7%) of the BMI between-groups variance was explained by the study location 
(East Asian vs. others) (total between Q = 0.963, p-value = 0.327, R2 index = 0.07). In addition, we 
found a significant difference in TAG levels in response to flavanol-containing products between the 
East Asian subgroup and the others with a more pronounced effect in the East Asian studies (total 
between Q = 7.419, p-value = 0.024, R2 index < 0.01). When grouping in North America and European 
countries, we detected a significant reduction of BMI and WC in the Europe group but not in the 
American one, whereas the LDL-cholesterol reduction resulted significant in the American group 
only. Statistical comparison between North America and Europe groups showed a difference in the 
BMI response (total between Q = 3.143, p-value = 0.076) and a 28% of the between-group variance 
explained by this factor (R2 index = 0.28). Within Europe, the studies carried out in countries of the 
Mediterranean area resulted in significant reductions of BMI, WC, total- and LDL-cholesterol and in 
an increase of HDL (p = 0.078). In the non-Mediterranean countries, we only detected a significant 
reduction of total-cholesterol. Comparison between the two subgroups indicated a significant 
difference in the WC reduction (Total between Q = 5.228, p-value = 0.022, R2 index < 0.01). 
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Table 3. Stratification analysis of the influence of baseline BMI, sex, smoking and country where the study was carried out on the effects (SDM) on BMI, WC, and blood 
lipids levels following supplementation with flavanol-containing products. 
Factor Baseline BMI Sex Smoking Country Where the Study Was Undertaken 
Subgroup <25.0 ≥25.0 Women Men Non-Smokers Smokers East Asian Countries All Other Countries North America All European Countries
European Countries 
Med 
Countries 
Non-Med 
Countries 
BMI 0.003 a −0.165 −0.102 −0.321 −0.148 NR −0.204 −0.126 −0.042 −0.235 −0.306 −0.176 
p-value (NS) (0.001) (NS) (0.003) (0.018)  (0.001) (0.007) (NS) (0.001) (0.024) (0.091) 
(n, N) (11, 477) (42, 2410) (15, 831) (8, 339) (24, 1046)  (23, 1511) (51, 2645) (15, 719) (20, 1051) (7, 392) (13, 659) 
WC −0.102 −0.362 −0.643 −0.932 −0.252 NR −0.217 −0.355 −0.123 −0.573 −1.279 −0.181 
p-value (NS) (0.000) (0.037) (0.024) (0.008)  (0.055) (0.000) (NS) (0.006) (0.001) (NS) 
(n, N) (3, 253) (36, 2002) (9, 464) (5, 266) (16, 750)  (19, 1458) (27, 1471) (6, 206) (13, 757) (5, 269) (8, 488) 
TC −0.047 −0.165 −0.493 −0.100 −0.221 0.147 −0.195 −0.223 −0.303 −0.254 −0.255 −0.252 
p-value (NS) (0.011) (0.012) (NS) (0.001) (NS) (0.054) (0.002) (0.027) (0.032) (0.003) (0.003) 
(n, N) (19, 504) (50, 2863) (15, 873) (14, 557) (41, 1572) (2, 88) (37, 2297) (75, 3515) (23, 1097) (30, 1296) (15, 609) (15, 639) 
LDL-C −0.062 −0.195 −0.545 −0.131 −0.156 −0.341 −0.236 −0.234 −0.379 −0.185 −0.246 −0.140 
p-value (NS) (0.002) (0.004) (NS) (0.039) (NS) (0.017) (0.001) (0.006) (NS) (0.042) (NS) 
(n, N) (13, 396) (48, 2698) (15, 868) (10, 416) (42, 1764) (2, 88) (31, 2334) (74, 3392) (25, 1117) (27, 1176) (12, 537) (15, 639) 
HDL-C 0.229 0.176 0.226 0.272 0.090 0.152 0.105 0.176 0.286 0.165 0.320 0.029 
p-value (NS) (0.063) (NS) (NS) (NS) (NS) (NS) (0.008) (0.095) (NS) (0.078) (NS) 
(n, N) (17, 455) (52, 2872) (15, 902) (16, 634) (45, 1945) (2, 88) (37, 2410) (75, 3518) (22, 978) (34, 1495) (15, 679) (18, 816) 
TAGs −0.058 −0.098 −0.067 0.109 −0.051 0.089 −0.196 −0.052 −0.098 −0.185 −0.161 −0.203 
p-value (NS) (NS) (NS) (NS) (NS) (NS) (0.034) (NS) (NS) (0.099) (NS) (NS) 
(n, N) (23, 596) (53, 2599) (16, 887) (18, 781) (55, 2243) (2, 88) (35, 1975) (83, 3796) (23, 921) (41, 1969) (18, 939) (24, 1100) 
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a Standardized difference in means (SDM); BMI: Body Mass Index; WC: Waist Circumference; TC: Total Cholesterol; LDL-C: Low density Lipoprotein Cholesterol; HDL-C: 
High Density Lipoprotein Cholesterol; TAGs: Triacylglycerides; Med: Mediterranean; p-value < 0.05 was considered significant ; p-value < 0.1 and ≥ 0.05 was considered 
marginally significant ; NS: No significant change/effect; (n): Number of studies included; (N): Total number of participants; NR: Not reported. 
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3.4.2. Stratification by the Individuals’ Medication and Health/Disease Status 
The influence of medication on the response to the consumption of the flavanol-containing 
products was also explored (Table 4). The subgroup including participants without any reported 
medication showed significant reductions of BMI, WC, total- and LDL-cholesterol as well as a 
reduction of TAGs (p = 0.063). In contrast, in the subgroup of studies including participants under 
medication the effects did not reach statistical significance. Further comparison between the two 
subgroups (Yes vs. No medication) revealed no significant differences between them (total between 
Q = 2.59, p-value = 0.107) but 34% of the between-groups variance for the BMI response was 
explained by this factor (R2 index = 0.34). 
Regarding health/disease status, participants were stratified as healthy, at risk or with a 
reported disease. Both in healthy subjects and in participants with a disease, the total- and 
LDL-cholesterol levels were significantly reduced. Studies conducted with volunteers categorized as 
at a risk exhibited the most significant reduction of BMI and WC in response to the flavanols. 
Stratification of the studies by the type of disorder showed a significant reduction of BMI and WC in 
overweight and/or obese individuals, a significant increase of HDL-cholesterol levels in patients 
with a dyslipidemia and a significant reduction of LDL-cholesterol in patients with diabetes or 
hypertension (Table 4). Comparison between each of the subgroups against the healthy subgroup 
was not significant for any of the variables investigated. 
3.4.3. Stratification by the Source/Administration Form of the Flavanols and the Diet during the 
Intervention 
Among the sources of flavanols investigated, our meta-analysis confirmed that 
supplementation with tea derived products significantly impacts on all the investigated variables 
except for TAGs (Table 5). Studies carried out with cocoa as the source of flavanols exhibited a 
significant effect on total-, LDL-cholesterol and TAGs levels whereas intervention with the 
apple-derived products appears to only modulate total- and LDL-cholesterol levels. Statistical 
comparison between the sources of flavanols highlighted a significant difference in the effect on BMI 
between tea and cocoa products (p-value = 0.012) with a 29% of the between-groups variance 
explained by this factor (R2 index = 0.29). The apple group resulted also significantly more efficient 
than the cocoa or tea groups in the reduction of total-cholesterol. In addition, the apple products 
showed a greater effect on LDL-cholesterol than the tea derived products. 
Regarding the supplementation form, the results showed that the administration of tea as solid 
extracts caused a significant and efficient modulation of all the variables investigated except for 
HDL and TAGs, whereas the tea beverages were significant at reducing only BMI and 
LDL-cholesterol (Table 5). Statistical comparison between liquid and solid tea-flavanols 
administration pointed out at a difference between the two subgroups at reducing LDL cholesterol 
(p-value = 0.096) with 11% of the between-group variance explained by this factor (R2 index = 0.11). A 
very limited number of studies have reported so far the effects of tea purified epigallocatechin 
gallate (EGCG), one of the main flavanols present in tea. Overall, these studies only support a 
significant reduction of BMI by this compound. Of note, and as opposed to tea products, the purified 
EGCG appears to reduce the levels of HDL (results not significant) and increase those of TAGs (p = 
0.077) (Table 5). Comparison between the EGCG subgroup and the tea drink or the tea extract 
subgroups indicated that the form of administration (as a purified compound or as a mixture) 
partially contributed to explaining the between groups variances for HDL (total between Q = 5.211, 
p-value = 0.022, R2 index = 0.10, EGCG vs. tea drink; total between Q = 3.835, p-value = 0.050, R2 index 
= 0.12, EGCG vs. tea extract) and for TAGs (total between Q = 3.282, p-value = 0.070, R2 index = 0.06, 
EGCG vs. tea drink; total between Q = 3.765, p-value = 0.052, R2 index = 0.09, EGCG vs. tea extract). 
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Table 4. Analysis of the influence of medication and health status on the effects (SDM) of the supplementation with flavanols on BMI, WC, and blood lipids levels. 
Factor Medication Health Status Type of Disorder
Subgroup Yes No Healthy Individuals Individuals at Risk Individuals with a Disease Overweight/Obese Lipid Disorders Glucose Disorders Blood Pressure Disorders 
BMI −0.053 a −0.222 −0.119 −0.195 −0.128 −0.191 −0.063 −0.028 −0.054 
p-value (NS) (0.001) (NS) (0.009) (0.069) (0.011) (NS) (NS) (NS) 
(n, N) (15, 744) (28, 1312) (18, 868) (26, 1753) (25, 1008) (22, 1488) (4, 179) (5, 265) (5, 225) 
WC −0.363 −0.445 −0.092 −0.392 −0.169 −0.426 NI −0.057 NI 
p-value (NS) (0.003) (NS) (0.000) (NS) (0.000)  (NS)  
(n, N) (5, 309) (21, 1237) (4, 250) (26, 1485) (9, 466) (25, 1447)  (4, 188)  
TC −0.205 −0.296 −0.266 −0.161 −0.241 −0.148 −0.227 −0.372 −0.515 
p-value (0.089) (0.001) (0.015) (NS) (0.014) (NS) (NS) (NS) (NS) 
(n, N) (24, 1174) (47, 2169) (38, 1520) (32, 2243) (38, 1859) (24, 1813) (9, 491) (8, 463) (5, 275) 
LDL-C −0.200 −0.289 −0.210 −0.192 −0.311 −0.187 −0.336 −0.579 −0.754 
p-value (NS) (0.004) (0.028) (0.061) (0.003) (0.082) (NS) (0.042) (0.041) 
(n, N) (21, 1020) (43, 2311) (37, 1782) (29, 2049) (36, 1756) (23, 1742) (9, 491) (6, 408) (4, 146) 
HDL-C 0.162 0.128 0.163 0.229 0.091 −0.062 0.476 0.032 0.115 
p-value (NS) (NS) (NS) −0.055 (NS) (NS) −0.005 (NS) (NS) 
(n, N) (25, 1212) (48, 2042) (37, 1670) (32, 2187)) (39, 1881) (20, 1541) (12, 654) (8, 488) (6, 301) 
TAGs −0.165 −0.135 −0.144 −0.08 −0.103 −0.008 −0.258 0.065 −0.251 
p-value (NS) −0.063 (NS) (NS) (NS) (NS) (NS) (NS) (NS) 
(n, N) (23, 1132) (63, 3019) (45, 2669) (31, 1205) (39, 1931) (24, 912) (12, 585) (7, 536) (6, 250) 
a Standardized difference in means (SDM); BMI: Body Mass Index; WC: Waist Circumference; TC: Total Cholesterol; LDL-C: Low density Lipoprotein Cholesterol; HDL-C: 
High Density Lipoprotein Cholesterol; TAGs: Triacylglycerides; p-value < 0.05 was considered significant ; p-value < 0.1 and ≥ 0.05 was considered marginally significant ; 
NS: No significant change/effect; (n): Number of studies included; (N): Total number of participants. 
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Table 5. Analysis of the influence of the original source of flavanols and of the diet (during the 
intervention) on the effects (SDM) of the supplementation on BMI, WC, and blood lipids levels. 
Factor Source of Flavanols 
Diet during 
Supplementation 
Subgroup 
Cocoa 
Products 
Apple 
Products 
Tea 
Products 
Tea 
Drinks 
Tea 
Extracts 
Tea Purified 
EGCG 
Controlled Usual 
BMI 0.001 a −0.11 −0.224 −0.223 −0.212 −0.290 −0.162 −0.149 
p-value (NS) (NS) (0.000) −0.007 (0.002) (0.022) (0.030) (0.001) 
(n, N) (21, 1014) (5, 319) (46, 2704) (20, 1167) (26, 1537) (7, 384) (23, 1032) (49, 2990) 
WC −0.106 −0.206 −0.354 −0.22 −0.506 −0.465 −0.500 −0.164 
p-value (NS) (NS) (0.000) (NS) (0.000) (NS) (0.000) (0.084) 
(n, N) (8, 430) (2, 155) (34, 2228) (16, 1074) (17, 1110) (2, 171) (18, 903) (27, 1868) 
TC −0.177 −1.352 −0.143 −0.083 −0.208 −0.051 −0.215 −0.213 
p-value −0.018 −0.041 (0.036) (NS) (0.008) (NS) (0.032) (0.003) 
(n, N) (38, 1625) (7, 402) (65, 3666) (36, 2051) (26, 1615) (7, 437) (39, 1682) (73, 4130) 
LDL-C −0.252 −0.587 −0.191 −0.119 −0.270 −0.216 −0.184 −0.260 
p-value −0.013 −0.007 (0.008) −0.045 (0.000) (NS) (0.062) (0.000) 
(n, N) (35, 1577) (8, 386) (61, 3723) (35, 2235) (26, 1488) (7, 206) (38, 1540) (67, 4186) 
HDL-C 0.16 0.197 0.150  0.17 0.13 −0.291 0.245 0.104 
p-value (NS) (NS) (0.031) −0.071 (NS) (NS) (0.008) (NS) 
(n, N) (37, 1603) (7, 386) (66, 3820) (38, 2292) (27, 1484) (7, 437) (40, 1759) (72, 4169) 
TAGs −0.183 −0.173 −0.050 −0.047 −0.053 0.314 −0.139 −0.105 
p-value −0.047 (NS) (NS) (NS) (NS) −0.077 (NS) (NS) 
(n, N) (39, 1691) (10, 455) (69, 3700) (38, 2121) (30, 1544) (7, 437) (46, 1939) (73, 3922) 
a Standardized difference in means (SDM); BMI: Body Mass Index; WC: Waist Circumference; TC: 
Total Cholesterol; LDL-C: Low density Lipoprotein Cholesterol; HDL-C: High Density Lipoprotein 
Cholesterol; TAGs: Triacylglycerides; p-value < 0.05 was considered significant ; p-value < 0.1 and ≥ 
0.05 was considered marginally significant ; NS: No significant change/effect; (n): Number of studies 
included; (N): Total number of participants; EGCG: Epigallocatechin gallate. 
Regarding the type of diet (controlled vs. usual) during supplementation with the 
flavanol-containing products, the reducing effects on BMI, WC, total- and LDL-cholesterol remained 
significant or marginally significant in both subgroups. The levels of TAGs were also reduced 
although not significantly. We detected, however, a significant increase in the HDL-cholesterol 
levels only in the subgroup that followed a controlled diet (Table 5). Further, statistical comparison 
of the two subgroups highlighted a significant difference on the reduction of WC between them 
(total between Q = 4.761, p-value = 0.029) and a 7% explanation of the between-groups variance by 
this factor (R2 index = 0.07). 
3.4.4. Multiple Meta-Regression Analysis of BMI Modulators of the Response to 
Flavanol-Containing Products Consumption 
Multiple meta-regression analysis was performed (Table 6) to derive the independent effect of 
some of the covariates previously found to partially explain some of the between-groups variance 
for BMI, i.e., baseline BMI (64%), country where the study was carried out (East-Asian vs. all other 
countries) (7%), medication use (34%) and source of flavanols (tea vs. cocoa products) (29%).  
Although sex also appeared to contribute greatly to the BMI between-groups variance (R2 = 1), it 
was not included in the multiple regression due to the limited number of studies clearly reporting 
sex and used in the analysis. The full model reached statistical significance, with a large proportion 
of variance (94%) accounted for and a considerable number of studies included (n = 40 studies). Both 
medication and source of flavanols were significantly correlated with the reducing effect on BMI, 
once controlled the influence of the other predictor. In particular, higher effects of the 
flavanols-products on BMI were found in the absence of the medication and with the consumption 
of tea products. 
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Table 6. Main results of the multiple random-effects meta-regression model for the contribution of 
the covariates, medication and source of flavanols, on BMI response (Standardized difference in 
means). 
Covariate Coefficient SE 95% Lower 95% Upper Z p-Value 
Intercept −0.0679 0.0899 −0.2440 0.1082 −0.76 0.4500 
Medication (No vs. Yes) 0.2481 0.0995 0.0530 0.4431 2.49 0.0127 
Source of flavanols (Cocoa vs. Tea) −0.3278 0.1022 −0.5282 −0.1274 −3.21 0.0013 
Test of the Model 
QR 15.64 
df 2 
p-value 0.0004 
R2 0.94 
Number of studies included 40 (54% of the total studies used in the meta-analysis) 
SE: standard error for each regression coefficient; Z: statistic for testing the statistical significance of 
each predictor; P: probability level; QR: statistic for testing the statistical significance of the full 
meta-regression model; df: degrees of freedom; R2: proportion of total between-studies variance 
explained by the model analog. 
4. Discussion 
The consumption of flavanols may contribute to improve cardiometabolic health via the 
moderation of a range of associated risk factors. Recent meta-analyses (Table S3) [138–151] suggest 
that the consumption of flavanol-containing tea and tea products could reduce total- and 
LDL-cholesterol as well as body mass index (BMI) and waist circumference (WC), while chocolate 
and cocoa flavanols also appear to regulate blood lipid levels. Nonetheless, the results of these 
analyses are inconsistent, partly due to the large heterogeneity of the clinical trials included. In 
addition, some of the anthropometric indicators of obesity such as BMI and WC have not yet been 
systematically investigated. We herein present the largest meta-analysis investigating the impact of 
flavanol-containing tea, cocoa and apple products, three major dietary sources of these bioactive 
compounds [152] on several biomarkers of lipid metabolism and anthropometric variables, such as 
BMI and WC. Our analysis confirms that the intake of these products is significantly associated with: 
(1) reduced BMI and WC; and (2) a more favorable lipid profile with a decrease in total- and 
LDL-cholesterol, and TAG plasma levels, and an increase in HDL-cholesterol levels. In addition, our 
analyses show that the changes in these biomarkers following consumption of the 
flavanol-containing products can be influenced by a number of factors and thus, the benefits of these 
products can significantly vary between specific population subgroups. It is of utmost interest to 
clarify the impact of these factors in order to discern which population subgroups could most benefit 
of the intake of these bioactive compounds. 
4.1. Baseline BMI 
There is evidence that baseline BMI may be a potential factor with an impact on the individuals’ 
response to supplementation with different natural products. For instance, treatment with natural 
probiotics has been shown to significantly increase HDL only in patients with a baseline BMI ≥ 29 
kg/m2 [153] or significantly reduce BMI only in participants with a baseline BMI ≥ 25 kg/m2 [154]. 
Regarding flavanol-containing products, a previous meta-analysis of the effects of black tea on blood 
cholesterol failed to detect differences in the modulation of cholesterol levels between individuals 
with normal weight or overweight and obese phenotype, but the results of this meta-analysis were 
estimated using a very small number of trials per subgroup (4 and 5, respectively) [141]. Our 
stratification approach by baseline BMI provides some evidence that the changes following 
consumption of flavanol-containing products on BMI, WC and cholesterol levels are more 
pronounced in individuals with a baseline BMI ≥ 25 kg/m2 and supports the fact that 
supplementation with these products may have a better impact on these risk factors in overweight 
and/or obese people. Nevertheless, it is not yet clear whether there is a general better efficacy of 
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natural treatments in overweight and/or obese people, or if the effects may vary depending on the 
biomarkers or the products investigated. More trials in individuals with a normal BMI < 25.0 kg/m2 
are still needed to further compare and demonstrate significant differences in the benefits of 
flavanol-containing products in relation to body weight, since most are conducted in populations of 
greater cardiometabolic risk, who are often obese in nature. 
4.2. Sex 
Understanding the differing responses by sex is becoming increasingly important. Previous 
work has shown that the reducing effects of green tea on total and LDL-cholesterol were 
significantly greater in men than in women, giving preliminary evidence of that supplementation 
with flavanol-containing green tea could have a different effect depending on the sex of the 
individuals [142]. Our results also support differences between women and men in their capacity to 
regulate the levels of total and LDL cholesterol in response to the consumption of 
flavanol-containing products with women exhibiting a more efficient reduction than men. A recent 
meta-analysis looking at the effects of flavonols (another flavonoids class) on lipids levels, failed to 
detect a difference between men and women, possibly due to the very low number of trials and 
participants in the two subgroups [7]. Comparing the regulation of cardiometabolic risk factors 
between women and men is complex because of the hormonal protection in premenopausal women 
[155]. We were not able to stratify our analyses based on the age or menopausal status of the women, 
as these factors were not sufficiently well characterized in the trials selected for the meta-analyses. 
Nevertheless, our results point out to a different response to flavanols consumption between sexes 
and reinforce the need to further investigate this factor in future trials specifically designed for this 
purpose. 
4.3. Country Where the Study Was Carried Out 
Ethno-cultural differences are associated with the risk of development of cardiometabolic 
disorders [156] and thus, it is important to explore and clarify whether different ethnic groups differ 
in their responses to consumption of plant bioactives as effective treatment against these diseases. 
Unfortunately, most of the clinical trials included in the present meta-analysis have not clearly 
identified the ethnicity of the participants. In the absence of this information, we have explored the 
potential influence of the country where the studies were carried out. A common comparison is that 
between studies undertaken in Asian countries vs. non-Asian ones. It has been reported that Asians 
showed a more marked decrease in the levels of TAGs in response to ϖ-3 fatty acids 
supplementation as compared to subjects within a USA/European group but, no significant 
differences were found for total cholesterol or BMI [157]. Flavonols have also been shown to 
significantly reduce TAGs, total and LDL-cholesterol in studies conducted in Asian countries as 
compared to those in the EU/European subgroup [7]. Regarding flavanol-containing products, 
previous meta-analyses have suggested that tea and tea extracts reduce BMI and WC both in Asian 
and non-Asian trials [140] and that, cocoa products significantly reduce LDL-cholesterol in 
European countries as compared to USA [149]. Nevertheless, these analyses were all underpowered. 
Our stratification analysis by country included, in general, a big number of studies per subgroup 
and showed no apparent differences in the responses to the consumption of tea, cocoa and apple 
products between East Asian countries and all other countries except for TAGs which were 
significantly reduced only in the Asian subgroup. We also found some different responses between 
North American (USA/Canada) and European subgroups, as well as between European 
Mediterranean and non-Mediterranean ones. This may be partially related to features such as the 
ethnicity of the participants but also to other factors associated with the life-style of the country. 
More studies are needed in order to understand the influence of this factor in the response to 
interventions with plant natural compounds.  
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4.4. Health and Medication Status 
Previous meta-analyses had suggested that the consumption of green tea [146,147], black tea 
[139], and cocoa products [149] had moderating effects on lipid levels both in healthy subjects and in 
patients with hyperlipidemia or at a higher cross-over or cross-over or s risk. Other bioactive 
compounds such as flavonols also had a more pronounced effect in the disease subgroup than in the 
healthy subgroup as significantly evidenced for LDL-cholesterol [7]. Our results show and 
corroborate a significant reduction of total- and LDL-cholesterol by the flavanol-containing tea, 
cocoa and apple products both in healthy participants and in individuals with a disease. On the 
other hand, BMI and WC were reduced and HDL increased in the three subgroups of healthy, “at 
risk” and individuals with a disease but the results reached statistical significance in the “at risk” 
group only. As a whole, these results support a metabolic benefit of the consumption of plant 
bioactive compounds, and in particular of flavanols, regardless of the health status of the 
individuals.  
An important consideration regarding the use of plant bioactive compounds as modulators of 
cardiometabolic risk biomarkers is their potential use as treatment on their own or as coadjuvants in 
combination with pharmacological drugs [158]. Our results show that the use of flavanol-containing 
products in the absence of medication was significantly associated with the reduction of BMI, WC, 
total and LDL cholesterol, as well as TAGs giving some evidence of their efficacy as therapeutics. 
The number of clinical trials in which the flavanols were supplemented in combination with other 
drugs was in general smaller than studies carried out in the absence of medication (see Table 4) thus 
the pooled results did not reach significance. Nonetheless, these data point to a modulatory effect of 
the flavanol-containing products in medicated individuals. Whether the combined therapy is more 
efficient and safe than individual treatment with drugs or with natural plant bioactives warrants 
further investigation. 
4.5. Source and Form of Administration of the Flavanols 
Our results confirm that the flavanol-containing tea products are effective regulators of blood 
cholesterol (total, LDL and HDL) as well as of BMI and WC. The cocoa or apple products were 
effective at reducing total- and LDL-cholesterol and the cocoa products were also able to 
significantly decrease the levels of TAGs. These results might suggest that the metabolic regulatory 
efficacy of these three flavanol-containing products could be ranked as tea > cocoa > apple but 
caution should be taken with this interpretation due to the differences in the number of studies 
carried out with each source of flavanols as well as the differences in the doses and the composition 
of the products. Further studies are needed to corroborate this comparison. Our analysis also 
suggests that the administration of tea as a solid extract might be more efficient than tea beverages at 
reducing WC and total cholesterol. Earlier meta-analyses had suggested that the type of 
administration of green or black tea either in solid form (extracts and, capsules) or as a drink did not 
differ at reducing total- and LDL-cholesterol [139,146,147]. Unlike those previous analyses, where 
the number of studies per subgroup was very small, our stratification between tea drinks and tea 
extracts included a considerable number of studies per subgroup (>15) and gives preliminary 
evidence of a potentially higher efficacy of the tea when administered as a solid powder. We may 
hypothesize that this could be partially related to the presence of higher doses of the bioactive 
flavanols in such extracts. 
4.6. Magnitude of the Changes 
An interesting issue worth discussing here is the magnitude of the changes attributed to the 
intake of the flavanol-containing products and to the extent these changes can contribute to the 
regulation of the analyzed biomarkers in comparison with other approaches, i.e., drugs, lifestyle 
changes, or other natural compounds. Based on the Cohen guidelines [159], the effects of the 
flavanol-containing products (expressed as SDM) are, in general, small (≤0.2) or medium (between 
0.2 and 0.5) although changes in some specific risk markers in some specific subgroups can be 
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considered high (≥0.8). We used the same random effects model to generate the overall size effects 
by computing the difference in means (Table S4) and compare these values to some of the reported 
effects of pharmacological, behavioral or dietary interventions on BMI, WC and lipid levels. Some of 
the most potent reducing effects on BMI can be achieved with restricted energy diet (−2.7 kg/m2) 
[160], pharmacological interventions (−1.3 kg/m2) [161] or behavioral (diet, exercise) interventions 
(−0.9 to −1.2 kg/m2) [162,163]. These reductions constitute between 5% and 10% of the WHO 
established limit values for overweight (BMI = 25.0–29.9 kg/m2) and obesity (BMI ≥ 30.0 kg/m2). 
Alternatively, intervention with probiotics [154] or nutraceuticals (e.g., lipoic acid) [164] shows a 
more modest but also significant reduction of BMI (approximately −0.5 kg/m2, ~2% change of the 
WHO values). On average, the size effect of the flavanol-containing products on BMI was smaller 
(−0.15 kg/m2, Table S3) but, notably, this effect may be enhanced in specific subpopulations (up to 
−0.91 kg/m2 in studies conducted in European Mediterranean countries), more similar to other 
behavioral or dietary interventions. WC can also be significantly and efficiently reduced by brisk 
walking (−2.83 cm, ~3% of the established 102/88 cm risk values) [162] and, more modestly (−0.53 cm, 
~0.5% of the established risk values) by intervention with supplements such as ϖ-3 polyunsaturated 
fatty acids [165]. Along these lines, intervention with the flavanol-containing products significantly 
reduces WC by 1.7 cm and can reach reducing values of −4.58 cm in studies conducted in European 
Mediterranean countries.  
Regarding the cholesterol lowering effects, statins remain, at present, the first-choice agents. 
The pooled effects of various statins on total- and LDL-cholesterol were −0.89 mmol/L (~17% of the 
desirable 5.17 mmol/L limit level) and −0.92 mmol/L (~27% of the near optimal 3.36 mmol/L level), 
respectively [166]. Intervention with natural products such as red yeast rice or spirulina can be as 
effective as the statins, whereas other plant dietary bioactive compounds such as soluble fiber, 
sterols/stanols, probiotics and flavonols also significantly reduce total- and LDL-cholesterol by 0.5–
0.1 mmol/L [7,167]. In this context, the flavanol-containing products show a similar efficiency at 
lowering total cholesterol (−0.13 mmol/L) and LDL cholesterol (−0.17 mmol/L). Again, in specific 
subgroups (e.g., supplementation with flavanol-containing apple products) the reduction of total 
cholesterol was much more efficient (−0.44 mmol/L). These results are very relevant considering that 
the reduction of LDL-cholesterol by 1 mmol/L has been associated with a 23% reduction of CVDs 
risk [168] and reinforce the interest in understanding the influence of different factors on the 
regulatory efficiency of plant bioactive compounds, in general, and of flavanols in particular. 
4.7. Additional Recent Evidences 
Since the completion of this meta-analysis, additional RCTs investigating the effects of tea or 
cocoa products containing flavanols on lipid and anthropometric variables have been added to the 
existing literature [111,169–183]. The heterogeneity of these trials remains high with population 
samples including mixed sexes and ages, obese, overweight, healthy, hyperlipidemic and/or diabetic 
subjects, etc. The products were administered in different forms, mostly as green tea 
extracts/capsules or cocoa drinks and at different doses and intervention periods. Some of these 
studies further support the reduction of total- and LDL-cholesterol by green tea or cocoa flavanols or 
the increase of HDL by dark chocolate or cocoa [111,169–171]. Others show no significant effects on 
these variables [175]. Noteworthy, some of these trials included stratification analyses by baseline 
conditions, medication, disease, age, sex, or even genotype and further point to specific responses in 
some subgroups [169,172,174,176,179]. Likewise, the intake of a cocoa product caused a greater 
increased of HDL in normocholesterolemic patients than in dyslipidemic patients [176], green tea 
capsules caused a significant reduction of total-cholesterol in women with a cholesterol baseline 
value above 5.17 mmol/L [169] or of LDL-cholesterol in patients not receiving anti-hyperlipidemic 
drugs [179]. Of note, the interactions between two factors: baseline BMI and 
catechol-O-methyltransferase (COMT) genotype, was also recently investigated although the COMT 
genotype did not modify the effect of green tea extract on any of the variables investigated including 
BMI [172]. In our study, we were able to identify several factors that may contribute to explaining 
the heterogeneity on the BMI changes in response to the flavanol-containing products. By multiple 
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meta-regression analysis, we also found that supplementation with these products may be most 
effective at reducing BMI when specifically using tea products in non-medicated patients. These 
results highlight the importance of understanding not only the factors affecting the variability in the 
responses but also the interactions between these factors. 
5. Conclusions 
To the best of our knowledge, the meta-analysis conducted here is the largest one to date that 
compiles the evidence on the effects on various metabolic risk factors after supplementation with 
three sources of flavanols, tea, cocoa, and apple products. Our results show consistent and 
significant modulatory effects on BMI, WC and lipid levels. The size of these effects is modest but 
similar to that prompted by other natural products. We have also presented evidence of the 
influence of several factors on these beneficial effects that suggest that flavanols might be very 
effective in specific subpopulations such as overweight people or non-medicated individuals or 
when the source of these bioactive compounds is tea. Moreover, a combination of these factors may 
best explain interindividual variability in the response to the flavanols-containing products. 
Although the total number of studies included in the meta-analysis was quite large, the number 
of studies (and of participants) remained small in some of the subgroup analyses. In addition, many 
of the studies reported limited or unclear information about the potential factors that may influence 
the treatment. These limitations affect the capability of the meta-analysis to unequivocally detect 
moderator variables and limit the significance of our findings. More randomized comparison studies 
with larger number of well-phenotyped volunteers and providing detailed descriptions of the 
participants and study characteristics are still needed. This research is crucial for a better 
understanding of the factors most relevantly involved in the variability of the responses to the 
consumption of these compounds and to achieve maximum efficacy so that flavanols may become 
an effective non-pharmacological alternative to battle hyperlipidemia, overweight/obesity and 
associated cardiometabolic disorders in humans.  
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/7/746/s1. Figure 
S1: Forest plot of the meta-analysis evaluating the effects of supplementation with flavanols-containing tea, 
cocoa or apple products on human body mass index (BMI). A total of 74 studies (displayed in alphabetical 
order) were analysed. Pooled results are shown at the bottom using a random-effects model. SDM: 
Standardized difference in means, SE: standard error, 95% CI: lower and upper confidence limits for the 
average SDM, RW: relative weight; Figure S2: Forest plot of the meta-analysis evaluating the effects of 
supplementation with flavanols-containing tea, cocoa or apple products on human waist circumference (WC). 
A total of 46 studies (displayed in alphabetical order) were analysed. Pooled results are shown at the bottom 
using a random-effects model. SDM: standardized difference in means, SE: standard error, 95% CI: lower and 
upper confidence limits for the average SDM, RW: relative weight; Figure S3: Forest plot of the meta-analysis 
evaluating the effects of a prolonged supplementation with flavanols-containing tea, cocoa or apple products 
on human blood levels of total cholesterol. A total of 112 studies (displayed in alphabetical order) were 
analysed. Pooled results are shown at the bottom using a random-effects model. SDM: standardized difference 
in means, SE: standard error, 95% CI: lower and upper confidence limits for the average SDM, RW: relative 
weight; Figure S4: Forest plot of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human blood levels of LDL cholesterol. A total of 105 
studies (displayed in alphabetical order) were analysed. Pooled results are shown at the bottom using a 
random-effects model. SDM: standardized difference in means, SE: standard error, 95% CI: lower and upper 
confidence limits for the average SDM, RW: relative weight; Figure S5: Forest plot of the meta-analysis 
evaluating the effects of a prolonged supplementation with flavanols-containing tea, cocoa or apple products 
on human blood levels of HDL cholesterol. A total of 112 studies (displayed in alphabetical order) were 
analysed. Pooled results are shown at the bottom using a random-effects model. SDM: standardized difference 
in means, SE: standard error, 95% CI: lower and upper confidence limits for the average SDM, RW: relative 
weight; Figure S6: Forest plot of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human blood levels of triglycerides (TAGs). A total of 120 
studies (displayed in alphabetical order) were analysed. Pooled results are shown at the bottom using a 
random-effects model. SDM: standardized difference in means, SE: standard error, 95% CI: lower and upper 
confidence limits for the average SDM, RW: relative weight; Figure S7: Funnel plot and Eager statistics 
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(intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human BMI; Figure S8: Funnel plot and Eager statistics 
(intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human WC; Figure S9: Funnel plot and Eager statistics 
(intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human blood levels of total cholesterol; Figure S10: Funnel 
plot and Eager statistics (intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a 
prolonged supplementation with flavanols-containing tea, cocoa or apple products on human blood levels of 
LDL cholesterol; Figure S11: Funnel plot and Eager statistics (intercept and 2-tailed p-value) of the 
meta-analysis evaluating the effects of a prolonged supplementation with flavanols-containing tea, cocoa or 
apple products on human blood levels of HDL cholesterol; Figure S12: Funnel plot and Eager statistics 
(intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with 
flavanols-containing tea, cocoa or apple products on human blood levels of triglycerides (TAGs); Table S1: 
Mean content (mg/100 fresh weight, FW) in flavonoids of green and black tea infusions, cocoa powder and 
whole apple illustrative of the composition of the three main sources of flavanols examined in this study: tea, 
cocoa and apple (data are based on the Phenol-Explorer database); Table S2: Results of the meta-regression of 
the changes in BMI, WC and blood lipids levels vs. duration of the supplementation with the 
flavanol-containing tea, cocoa or apple products; Table S3: Summary of most recent meta-analysis looking at the 
effects of flavanol-containing tea or cocoa products on anthropometric measurements and blood lipids 
associated with the development of metabolic disorders; Table S4: Overall effect size estimations (DM) for the 
impact of flavanols containing products on BMI, WC and blood lipids levels. 
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